Related Experiment Videos
Ipratropium bromide and fenoterol by aerosolized solution
British Journal of Clinical Pharmacology
|July 1, 1982
Summary
Ipratropium bromide and fenoterol offer comparable peak bronchodilation for chronic airway obstruction. Combining these medications provides enhanced relief compared to individual use, suggesting benefits for small airway disease.
Area of Science:
- Pulmonology
- Pharmacology
- Respiratory Medicine
Background:
- Chronic partially reversible airways obstruction presents a significant clinical challenge.
- Understanding the comparative efficacy and duration of bronchodilators is crucial for patient management.
Purpose of the Study:
- To compare the bronchodilating effects of ipratropium bromide and fenoterol.
- To evaluate the duration of action for each drug and their combination.
- To assess the impact on small airways in patients with chronic obstruction.
Main Methods:
- Eight patients with chronic partially reversible airways obstruction participated.
- Administration of ipratropium bromide (0.5 mg) and fenoterol (2 mg).
- Measurement of bronchodilatation, FVC, and FEV1 over time compared to saline placebo.
Main Results:
- Equivalent peak bronchodilatation was observed between 1-2 hours for both ipratropium bromide and fenoterol.
- Ipratropium bromide demonstrated a longer duration of action (6 hours) than fenoterol (4 hours) compared to saline.
- The combination of ipratropium bromide and fenoterol yielded superior bronchodilation compared to either agent alone.
- Disproportionately greater increases in FVC than FEV1 suggested relief of small airway obstruction.
Conclusions:
- Both ipratropium bromide and fenoterol are effective bronchodilators for chronic partially reversible airways obstruction.
- The combination therapy offers additive benefits, particularly for patients with small airway involvement.
- The findings support the use of these agents in managing complex airway diseases.